Two years ago ‘this place’ had an entirely different set of projections leading the dynamic.
I expect this exampled people finding what they expect to find.
I’m as I was, except for having a bit more confidence .
Cheers
....another press update ;
https://thewest.com.au/business/hea...sapps-cough-diagnosis-software-ng-b881340740z
“TGA approval for ResApp’s cough diagnosis software
Daniel NewellThe West Australian
Wednesday, 2 October 2019 11:43AM
Daniel Newell
A TGA submission to use the app for adults will be made shortly, the company said. Credit: Austrade
Shares in ResApp shot up more than 10 per cent after the digital health hopeful won approval from the Australian Therapeutics Goods Administration for a smartphone test that can diagnose respiratory diseases in children.
The WA-founded group uses machine-learning algorithms developed at the University of Queensland, with funding from the Bill and Melinda Gates Foundation, to diagnose cough sounds recorded via an app.
The system looks for sound signatures in the cough and matches them to respiratory diseases, including asthma and pneumonia, allowing doctors to consult over the phone or for patients to diagnose themselves.
The company said ResAppDx-EU — which runs on a smartphone and does not require any extra hardware — was now listed on the Australian Register of Therapeutic Goods.
A TGA submission to use the app for adults will be made shortly, the company said.
“Achieving TGA approval is an important regulatory milestone that allows us to sell ResAppDx-EU in Australia, our home market,” ResApp chief executive and managing director Tony Keating said.
“We believe that ResAppDx-EU will deliver strong health and economic benefits when used by clinicians in Australian emergency departments, urgent care clinics, GP offices and in the Australian telehealth industry, which has grown markedly in the last year.”
Upper respiratory tract infections account for up to four million visits to Australian GPs every year, with an additional three million patients visiting doctors for lower respiratory tract complaints.
Bronchiolitis and croup account for most winter hospitalisations for children.
The app recently won CE Mark approval in the European Union for adult and paediatric use, and approvals are pending for paediatric use in the US.
ResApp shares were up 11.3 per cent to a 12-month high of 27.5¢ at 11.35am.”
- Forums
- ASX - By Stock
- RAP
- rap chart
rap chart, page-1361
-
- There are more pages in this discussion • 3,281 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)